In summary, our findings suggest that BAG2 specifically binds to structural mutant p53 and promotes mutant p53 aggregation by recruiting HSP90, reducing the apoptosis of breast cancer cells to chemotherapeutic drugs, thereby conferring chemoresistance, and contributing to poor clinical outcomes in breast cancer (Figure 7D). Here, BAG2 is linked to breast carcinoma.